Pomerantz Law Firm Alerts Corcept Therapeutics Investors About Class Action Lawsuit Deadlines

Investor Alert: Class Action Lawsuit Against Corcept Therapeutics

Pomerantz LLP has issued a critical update for investors who have experienced financial losses in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT). The firm has filed a class action lawsuit against the company, alleging potential securities fraud and unlawful business practices by the company’s management.

Background of the Lawsuit

The class action suit centers around the concerns raised when Corcept announced on December 31, 2025, that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) regarding a New Drug Application for their product, relacorilant. This medication was under consideration as a treatment for patients suffering from hypertension secondary to hypercortisolism. The FDA concluded that it could not favorably evaluate the benefit-risk balance of relacorilant without further evidence of its efficacy, which significantly impacted investor confidence.

As a direct consequence of this news, Corcept's stock plummeted sharply, dropping $35.40 per share, equivalent to a 50.4% decrease, closing at $34.80 on the same day. This rapid decline has prompted Pomerantz LLP to alert and represent affected shareholders through legal action, as they may have suffered considerable financial losses.

Who Should Get Involved?

Investors who purchased or otherwise acquired Corcept securities during the class period are encouraged to participate in this class action. If you believe you are eligible to seek the court’s appointment as Lead Plaintiff in this case, your request must be made by April 21, 2026. Inquiries can be directed to Danielle Peyton at Pomerantz LLP via email or by phone at 646-581-9980 (toll-free 888-4-POMLAW, Ext. 7980). Prospective participants should include their mailing address, phone number, and details about their stock purchases in their communication.

Pomerantz LLP's Commitment to Investors

Pomerantz LLP is recognized as one of the leading firms specializing in corporate, securities, and antitrust class-action litigation, with a legacy that spans over 85 years. Founded by Abraham L. Pomerantz, who is regarded as a pioneer in the field of securities law, the firm is dedicated to advocating for investors’ rights and seeking justice for victims of corporate misconduct.

The firm has successfully recovered millions in damages for its clients over the decades, reinforcing its status as a trusted ally for investors seeking redress from unscrupulous corporate practices. It remains committed to holding companies accountable and recovering losses for affected shareholders.

Next Steps for Investors

Investors are urged not to delay their response, as the deadline to become involved is fast approaching. More information regarding the lawsuit can be accessed through Pomerantz's official website, where a copy of the complaint is also available.
If you or someone you know has been affected by the developments surrounding Corcept Therapeutics, reaching out to Pomerantz LLP may be a crucial step towards reclaiming your financial standing.

Conclusion

As this legal action unfolds, it serves as a stark reminder of the importance of vigilance in the investment landscape. The Pomerantz Law Firm remains at the forefront, ensuring that investors have access to the necessary support and representation to navigate these challenges effectively. With their expertise and commitment, they aim to safeguard the interests of investors while pursuing justice in the face of corporate wrongdoing.